Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report third quarter 2026 financial results on Monday, November 2, 2026, after the close of the U.S. financial markets. The Company ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing ...

Travere Therapeutics reported durable biomarker data for FILSPARI in IgA nephropathy, but shares fell 4.5% as markets focus ...

Travere Therapeutics presented Phase 3 PROTECT biomarker findings suggesting FILSPARI may modify underlying disease ...

Ligand Pharmaceuticals (NASDAQ:LGND) reported third-quarter royalty revenue growth of 51% year over year to approximately $70 ...

Cytokinetics (CYTK) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results ...

Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.38 per share a year ago. These ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

In a report released yesterday, Vamil Divan from Guggenheim reiterated a Buy rating on Merck & Company, with a price target of $170.00. The company’s shares closed yesterday at $141.82. Divan covers ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Argenx Se (ARGX) and Boston Scientific (BSX) with bullish sentiments. According to TipRanks.com, CFA is a ...

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and nine months ended September ...

The new Kidney Care National Plan from the US Department of Health and Human Services focuses on preventing kidney failure, ...